City
Epaper

Initial findings on plasma therapy trial did not show promising evidence: AIIMS

By ANI | Updated: August 6, 2020 16:20 IST

The trial conducted by All India Institute of Medical Sciences (AIIMS) for convalescent plasma therapy on COVID-19 patients did not show much clinical benefit in reducing fatality risk caused due to the virus.

Open in App

The trial conducted by All India Institute of Medical Sciences (AIIMS) for convalescent plasma therapy on COVID-19 patients did not show much clinical benefit in reducing fatality risk caused due to the virus.

"These are initial analyses. There were two groups of 15 patients each on whom a randomised control trial was done to know the effectiveness of plasma therapy. One group received standard treatment protocol while the other group received convalescent plasma therapy along with standard treatment. It was noted that mortality was similar in both the groups with no much clinical benefits to the patients," Dr Randeep Guleria, Director at AIIMS told .

"It is also important to note that we need more evidence on it to conclude anything. Current evidence suggests that convalescent plasma is safe, does not cause any harm to a patient. But at the same time, it (plasma therapy) is not very effective and hence should be used prudently," Dr Guleria further said.

It may be noted that the Union Health Ministry in its clinical management protocol for COVID19 patients has described the use of convalescent plasma therapy as one of the investigational therapies.

The treatment protocol states that convalescent plasma therapy may be considered in patients with the moderate disease who are not improving (oxygen requirement is progressively increasing) despite the use of steroids.

The dose for convalescent plasma can be variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hours).

"There are special prerequisites while considering convalescent plasma. It includes ABO compatibility and cross-matching of the donor plasma. Recipients should be closely monitored for several hours post-transfusion for any transfusion related adverse events. However, the use of convalescent plasma should be avoided in patients with IgA deficiency or immunoglobulin allergy," read clinical guidelines.

Meanwhile, the Indian Council of Medical Research (ICMR) is also conducting trials to evaluate the efficacy of plasma therapy, however, results have not been published yet.

( With inputs from ANI )

Tags: All India Institute Of Medical SciencesAiims
Open in App

Related Stories

NationalBihar: Burnt Bodies of 2 Children Found Inside House in Patna, Probe Underway

NationalOdisha Sexual Harassment: Balasore Student Succumbs to Injuries After Self-immolation; CM Vows Action Against Culprits

NationalAIIMS Paramedical Admit Card 2025 to Be Released Today at aiimsexams.ac.in; Know How to Download

NationalAIIMS Delhi: Fire Breaks Out in Transformer Near Trauma Centre; Fire Tenders on Spot (Watch Video)

NationalCOVID Vaccine Has No Connection With Surge in Sudden Deaths Among Adults; Says ICMR Delhi and AIIMS Study

National Realted Stories

NationalMumbai Metro lines 2A and 7 cross 200 million rides: Official

NationalMinister Sirsa visits Norway e-waste facility to plan eco park in Delhi

NationalJamnagar homes shine with PM Surya Ghar scheme, power bills drop sharply

NationalTelangana to act on Kaleshwaram Commission report after debate in Assembly

NationalNeha Hiremath murder case: K'taka court denies bail to accused Fayaz